科源制药
(301281)
| 流通市值：23.13亿 | | | 总市值：36.39亿 |
| 流通股本：6885.20万 | | | 总股本：1.08亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 265,178,915.25 | 156,617,281.37 | 178,129,204.25 | 267,304,173.29 |
| 交易性金融资产 | 103,287,552.83 | 241,036,477.21 | 254,432,817.21 | 186,682,625.59 |
| 应收票据及应收账款 | 97,025,326.87 | 65,608,632.57 | 60,784,778.33 | 54,000,218.57 |
| 其中：应收票据 | 5,232,632.31 | 5,899,071.47 | 7,178,801.14 | 8,044,575.74 |
| 应收账款 | 91,792,694.56 | 59,709,561.1 | 53,605,977.19 | 45,955,642.83 |
| 应收款项融资 | 5,042,191.97 | 25,092,560.68 | 35,064,610.93 | 2,672,896.69 |
| 预付款项 | 5,740,534.95 | 6,795,685.39 | 2,822,334.61 | 12,730,997.51 |
| 其他应收款合计 | 26,391,580.71 | 26,846,030.35 | 27,114,153.9 | 2,926,156.52 |
| 存货 | 147,478,076 | 142,446,197.36 | 128,944,612.45 | 103,939,818.19 |
| 其他流动资产 | 5,771,867.53 | 15,724,251.43 | 3,442,356.88 | 13,602,924.61 |
| 流动资产合计 | 655,916,046.11 | 680,167,116.36 | 690,734,868.56 | 643,859,810.97 |
| 非流动资产: | | | | |
| 长期股权投资 | 189,963,369.18 | 187,915,079.94 | 187,915,079.94 | 184,007,854.35 |
| 其他权益工具投资 | 2,651,414.32 | 2,560,202.02 | 2,399,595.96 | 2,399,595.96 |
| 固定资产 | 301,417,714.87 | 301,909,780.02 | 293,850,296.08 | 296,915,139.6 |
| 在建工程 | 251,754,028.56 | 204,066,547.37 | 183,151,858.85 | 181,435,014.11 |
| 无形资产 | 115,364,508.26 | 105,628,011.35 | 107,168,952.49 | 88,956,234.23 |
| 开发支出 | 1,809,433.96 | 1,809,433.96 | 1,809,433.96 | - |
| 商誉 | 1,820,994.04 | 1,820,994.04 | 1,820,994.04 | 1,820,994.04 |
| 长期待摊费用 | 435,384.52 | 508,399.09 | 581,413.66 | 3,697,791.82 |
| 递延所得税资产 | 3,302,549.08 | 3,108,409.32 | 3,057,366.5 | 2,473,425.48 |
| 其他非流动资产 | 79,910,162.03 | 86,518,520.14 | 79,984,411.1 | 59,102,301.17 |
| 非流动资产合计 | 948,429,558.82 | 895,845,377.25 | 861,739,402.58 | 820,808,350.76 |
| 资产总计 | 1,604,345,604.93 | 1,576,012,493.61 | 1,552,474,271.14 | 1,464,668,161.73 |
| 流动负债: | | | | |
| 短期借款 | - | 3,478,384.98 | - | - |
| 应付票据及应付账款 | 37,960,534.08 | 36,556,250.99 | 42,245,994.51 | 53,267,584.5 |
| 应付账款 | 37,960,534.08 | 36,556,250.99 | 42,245,994.51 | 53,267,584.5 |
| 合同负债 | 2,609,206.23 | 5,122,448.52 | 20,243,924.87 | 2,388,856.12 |
| 应付职工薪酬 | 12,097,856.04 | 11,569,743.89 | 11,083,411.12 | 9,926,988.48 |
| 应交税费 | 4,828,562.93 | 3,450,699.12 | 2,258,655.12 | 907,825.62 |
| 其他应付款合计 | 36,727,423.07 | 36,191,836.24 | 36,014,632.69 | 25,588,182.82 |
| 其他流动负债 | 5,843,941.27 | 6,343,453.87 | 7,938,207.54 | 7,056,805.93 |
| 流动负债合计 | 100,067,523.62 | 102,712,817.61 | 119,784,825.85 | 99,136,243.47 |
| 非流动负债: | | | | |
| 长期借款 | 95,801,027.98 | 63,188,773.33 | 45,662,036.88 | - |
| 预计负债 | - | 381,419.92 | 381,419.92 | - |
| 递延收益 | 9,893,673.22 | 9,021,023.98 | 9,265,351.42 | 10,101,048.31 |
| 递延所得税负债 | 16,480,838.34 | 17,464,007.43 | 17,777,100.38 | 17,953,141.95 |
| 非流动负债合计 | 122,175,539.54 | 90,055,224.66 | 73,085,908.6 | 28,054,190.26 |
| 负债合计 | 222,243,063.16 | 192,768,042.27 | 192,870,734.45 | 127,190,433.73 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 108,290,000 | 108,290,000 | 108,290,000 | 108,290,000 |
| 资本公积 | 907,672,976.25 | 907,672,976.25 | 907,672,976.25 | 906,672,990.8 |
| 专项储备 | 4,082,820.42 | 3,141,035.11 | 2,567,776.94 | 2,158,354.86 |
| 盈余公积 | 50,211,217.05 | 50,211,217.05 | 50,211,217.05 | 46,773,352.27 |
| 未分配利润 | 311,078,707.68 | 313,138,531.03 | 290,053,664.53 | 272,725,893.74 |
| 归属于母公司股东权益合计 | 1,381,335,721.4 | 1,382,453,759.44 | 1,358,795,634.77 | 1,336,620,591.67 |
| 少数股东权益 | 766,820.37 | 790,691.9 | 807,901.92 | 857,136.33 |
| 股东权益合计 | 1,382,102,541.77 | 1,383,244,451.34 | 1,359,603,536.69 | 1,337,477,728 |
| 负债和股东权益合计 | 1,604,345,604.93 | 1,576,012,493.61 | 1,552,474,271.14 | 1,464,668,161.73 |
| 公告日期 | 2025-08-16 | 2025-04-25 | 2025-04-11 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |